ICYMI: Orphan drug development brings unique challenges

A newreport from the Tufts Center for the Study of Drug Development finds that it takes 2.3 years, or 18 percent, longer to develop an orphan drug compared with medicines to treat more common conditions. Although clinical trials for orphan diseases – defined as affecting fewer than 200,000 people in the U.S. – tend to be smaller than other studies and orphan drugs often qualify for expedited review pathways, the reality is that development of these medicines poses many unique challenges in addition to the usual high hurdles of drug develop ment. According to Tufts, the most common challenges include:
Source: The Catalyst - Category: Pharmaceuticals Tags: Rare Diseases Drug Development Source Type: news